93 related articles for article (PubMed ID: 38482176)
61. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review.
Kharawala S; Golembesky AK; Bohn RL; Esser D
Expert Rev Clin Immunol; 2020 Mar; 16(3):239-252. PubMed ID: 32073341
[No Abstract] [Full Text] [Related]
62. Current management of generalized pustular psoriasis.
Kodali N; Blanchard I; Kunamneni S; Lebwohl MG
Exp Dermatol; 2023 Aug; 32(8):1204-1218. PubMed ID: 36779681
[TBL] [Abstract][Full Text] [Related]
63. Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M; Camela E; Ruggiero A; Battista T; Martora F; Cacciapuoti S; Potestio L
Clin Cosmet Investig Dermatol; 2023; 16():1677-1690. PubMed ID: 37404368
[TBL] [Abstract][Full Text] [Related]
64. A review of disease burden and clinical management for generalized pustular psoriasis in China.
Lu J; Shi Y
Expert Rev Clin Immunol; 2022 Oct; 18(10):1023-1032. PubMed ID: 36040447
[TBL] [Abstract][Full Text] [Related]
65. Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis.
Pathak GN; Wang E; Dhillon J; Parikh PN; Esseghir R; Rao BK; Feldman SR
Ann Pharmacother; 2024 May; ():10600280241252688. PubMed ID: 38755971
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation.
Potestio L; Camela E; Cacciapuoti S; Martora F; Guerriero L; Fornaro L; Ruggiero A; Megna M
Expert Opin Drug Saf; 2023; 22(11):1003-1010. PubMed ID: 37768729
[TBL] [Abstract][Full Text] [Related]
67. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
[TBL] [Abstract][Full Text] [Related]
68. Clinical advances in biological therapy for generalized pustular psoriasis: a review.
Hsieh CY; Tsai TF
Expert Opin Biol Ther; 2024; 24(1-2):37-50. PubMed ID: 38247394
[TBL] [Abstract][Full Text] [Related]
69. Generalized pustular psoriasis: current management status and unmet medical needs in Japan.
Komine M; Morita A
Expert Rev Clin Immunol; 2021 Sep; 17(9):1015-1027. PubMed ID: 34402355
[TBL] [Abstract][Full Text] [Related]
70. A narrative review of the socioeconomic burden associated with generalised pustular psoriasis.
Zimmermann TM; Hofmann P; Chiu GR
Exp Dermatol; 2023 Aug; 32(8):1219-1226. PubMed ID: 37309747
[TBL] [Abstract][Full Text] [Related]
71. Clinical Disease Measures in Generalized Pustular Psoriasis.
Burden AD; Choon SE; Gottlieb AB; Navarini AA; Warren RB
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):39-50. PubMed ID: 35061231
[TBL] [Abstract][Full Text] [Related]
72. Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence.
Bhutani T; Farberg AS
Dermatol Ther (Heidelb); 2024 Feb; 14(2):341-360. PubMed ID: 38363460
[TBL] [Abstract][Full Text] [Related]
73. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis.
Krueger J; Puig L; Thaçi D
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):51-64. PubMed ID: 35061230
[TBL] [Abstract][Full Text] [Related]
74. Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review.
Choon SE; De La Cruz C; Wolf P; Jha RK; Fischer KI; Goncalves-Bradley DC; Hepworth T; Marshall SR; Gottlieb AB
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):265-280. PubMed ID: 37750484
[TBL] [Abstract][Full Text] [Related]
75. An update on generalized pustular psoriasis.
Gooderham MJ; Van Voorhees AS; Lebwohl MG
Expert Rev Clin Immunol; 2019 Sep; 15(9):907-919. PubMed ID: 31486687
[No Abstract] [Full Text] [Related]
76. Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: Should they be the same or different entities?
Chularojanamontri L; Rattanakorn K; Julanon N; Chuamanochan M; Griffiths CEM
Exp Dermatol; 2023 Aug; 32(8):1235-1245. PubMed ID: 37057764
[TBL] [Abstract][Full Text] [Related]
77. Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects.
Takeichi T; Akiyama M
Am J Clin Dermatol; 2020 Apr; 21(2):227-236. PubMed ID: 31813117
[TBL] [Abstract][Full Text] [Related]
78. Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond.
Sugiura K
Dermatol Ther (Heidelb); 2022 Feb; 12(2):315-328. PubMed ID: 35060076
[TBL] [Abstract][Full Text] [Related]
79. The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis.
Zheng M; Jullien D; Eyerich K
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):5-12. PubMed ID: 35061224
[TBL] [Abstract][Full Text] [Related]
80. Pathophysiology of Generalized Pustular Psoriasis.
Marrakchi S; Puig L
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):13-19. PubMed ID: 35061228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
